bullish
Alphamab (康宁杰瑞) IPO: Thoughts on Base-Line Valuation
550 Views14 Oct 2019 15:16
Alphamab, a China-based biotech company, is seeking to raise USD 200 to 300 million via a listing on the Hong Kong Stock Exchange. In our previous...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 2-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (1 Dec 2019) - Venus Medtech, Alphamab, CMC REIT, XD, BAM01 Dec 2019
- Alphamab (康宁杰瑞) IPO: You Will Likely Be Zeroed29 Nov 2019
- Alphamab (康宁杰瑞) Pre-IPO: Promising Readings from PHIP Updates18 Nov 2019
- Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi30 Jul 2019
- Alphamab (康宁杰瑞) IPO: Strong R&D Capability and Innovative Platforms24 Jul 2019
x